Arcus Biosciences (RCUS) Short Interest Ratio & Short Volume $14.49 -0.13 (-0.89%) (As of 09:35 AM ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Arcus Biosciences Short Interest DataArcus Biosciences (RCUS) has a short interest of 6.65 million shares, representing 13.82% of the float (the number of shares available for trading by the public). This marks a 4.89% increase in short interest from the previous month. The short interest ratio (days to cover) is 9.3, indicating that it would take 9.3 days of the average trading volume of 729,950 shares to cover all short positions.Current Short Interest6,650,000 sharesPrevious Short Interest6,340,000 sharesChange Vs. Previous Month+4.89%Dollar Volume Sold Short$101.75 millionShort Interest Ratio9.3 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares91,510,000 sharesFloat Size48,110,000 sharesShort Percent of Float13.82%Today's Trading Volume7,302 sharesAverage Trading Volume729,950 sharesToday's Volume Vs. Average1% Short Selling Arcus Biosciences? Sign up to receive the latest short interest report for Arcus Biosciences and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartRCUS Short Interest Over TimeRCUS Days to Cover Over TimeRCUS Percentage of Float Shorted Over Time Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Arcus Biosciences Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20246,650,000 shares $101.75 million +4.9%13.8%9.3 $15.30 10/15/20246,340,000 shares $112.73 million -4.1%13.2%10.1 $17.78 9/30/20246,610,000 shares $101.03 million -4.2%13.8%11.5 $15.29 9/15/20246,900,000 shares $123.86 million +2.4%14.2%11.5 $17.95 8/31/20246,740,000 shares $115.39 million -3.3%13.8%9.9 $17.12 8/15/20246,970,000 shares $109.64 million +5.3%14.4%9.6 $15.73 Get the Latest News and Ratings for RCUS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter. 7/31/20246,620,000 shares $108.90 million -0.3%13.7%9.3 $16.45 7/15/20246,640,000 shares $102.52 million +7.8%13.8%9.4 $15.44 6/30/20246,160,000 shares $93.82 million -22.1%12.8%8.7 $15.23 6/15/20247,910,000 shares $134.23 million +6.5%16.4%11.4 $16.97 5/31/20247,430,000 shares $112.04 million -1.5%15.5%11.5 $15.08 5/15/20247,540,000 shares $132.33 million -2.7%15.7%11.3 $17.55 4/30/20247,750,000 shares $118.11 million +13.3%16.4%10.3 $15.24 4/15/20246,840,000 shares $111.42 million -17.1%14.5%8.3 $16.29 3/31/20248,250,000 shares $155.76 million +3.4%17.4%9.7 $18.88 3/15/20247,980,000 shares $151.78 million +3.9%16.9%9.3 $19.02 2/29/20247,680,000 shares $146.92 million +2.1%16.2%8.6 $19.13 2/15/20247,520,000 shares $123.37 million +7.4%15.9%8.6 $16.41 1/31/20247,000,000 shares $105.91 million -2.1%22.3%8.7 $15.13 1/15/20247,150,000 shares $125.20 million -1.7%14.8%9.1 $17.51 12/31/20237,270,000 shares $138.86 million +7.4%15.1%9.6 $19.10 12/15/20236,770,000 shares $122.67 million +2.9%14.0%8.6 $18.12 11/30/20236,580,000 shares $99.09 million +9.3%13.7%9.1 $15.06 11/15/20236,020,000 shares $87.59 million -13.0%12.5%7.8 $14.55 10/31/20236,920,000 shares $108.68 million +0.6%14.4%8.3 $15.71 10/15/20236,880,000 shares $110.91 million +3.9%14.4%8.7 $16.12 9/30/20236,620,000 shares $118.83 million +1.4%13.8%8 $17.95 9/15/20236,530,000 shares $134.39 million -11.0%13.6%8 $20.58 8/31/20237,340,000 shares $150.47 million +2.5%15.5%7.4 $20.50 8/15/20237,160,000 shares $128.67 million -1.1%15.1%6.6 $17.97 7/31/20237,240,000 shares $144.08 million -6.7%15.2%6.8 $19.90 7/15/20237,760,000 shares $169.94 million -1.7%16.7%7.2 $21.90 6/30/20237,890,000 shares $160.25 million -18.1%16.9%7.3 $20.31 6/15/20239,630,000 shares $188.75 million -6.0%20.2%9 $19.60 5/31/202310,240,000 shares $210.33 million +18.0%21.5%9.6 $20.54 5/15/20238,680,000 shares $169.43 million +11.1%18.3%9 $19.52 4/30/20237,810,000 shares $139.41 million -3.2%16.6%8.4 $17.85 4/15/20238,070,000 shares $141.55 million +5.1%17.1%8.4 $17.54 3/31/20237,680,000 shares $140.08 million +15.1%16.4%7.6 $18.24 3/15/20236,670,000 shares $113.12 million -10.7%14.2%5.5 $16.96Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide 2/28/20237,470,000 shares $136.03 million +14.8%15.9%6.4 $18.21 2/15/20236,510,000 shares $127.92 million +0.6%14.0%5.6 $19.65 1/31/20236,470,000 shares $139.95 million +1.3%14.0%5.5 $21.63 1/15/20236,390,000 shares $130.23 million -12.8%13.7%5.3 $20.38 12/30/20227,330,000 shares $151.58 million -2.5%15.7%6.6 $20.68 12/15/20227,520,000 shares $233.12 million -0.5%16.1%7.6 $31.00 11/30/20227,560,000 shares $265.89 million +7.7%16.2%9.6 $35.17 11/15/20227,020,000 shares $210.95 million +4.8%15.1%10.3 $30.05 10/31/20226,700,000 shares $170.72 million -19.1%15.0%9.8 $25.48 10/15/20228,280,000 shares $220.58 million +1.4%18.6%13 $26.64 9/30/20228,170,000 shares $213.73 million -3.1%18.3%12.8 $26.16 9/15/20228,430,000 shares $226.43 million -0.5%18.9%12.6 $26.86 8/31/20228,470,000 shares $203.96 million +3.2%19.0%12.1 $24.08 8/15/20228,210,000 shares $229.88 million +4.7%18.4%10.5 $28.00 7/31/20227,840,000 shares $208.47 million +5.0%19.6%7.6 $26.59 7/15/20227,470,000 shares $216.93 million +4.5%17.0%7 $29.04 6/30/20227,150,000 shares $181.18 million +4.5%16.2%6.5 $25.34 6/15/20226,840,000 shares $148.15 million -2.8%15.5%4.8 $21.66 5/31/20227,040,000 shares $133.41 million -11.7%16.0%5.3 $18.95 5/15/20227,970,000 shares $154.38 million -14.9%18.1%6 $19.37 4/30/20229,370,000 shares $226.85 million +10.8%21.0%8.8 $24.21 4/15/20228,460,000 shares $270.55 million +48.2%19.0%8.5 $31.98 3/31/20225,710,000 shares $180.21 million +5.6%12.9%5.7 $31.56 3/15/20225,410,000 shares $171.23 million -5.6%12.1%8.3 $31.65 2/28/20225,730,000 shares $213.16 million -1.4%12.9%8.3 $37.20 2/15/20225,810,000 shares $172.56 million -4.4%13.2%8.6 $29.70 1/31/20226,080,000 shares $187.26 million -8.7%15.2%8.3 $30.80 1/15/20226,660,000 shares $238.49 million -20.6%15.8%9.6 $35.81 12/31/20218,390,000 shares $339.54 million +18.5%19.9%13.3 $40.47 12/15/20217,080,000 shares $286.88 million -5.2%16.8%10.9 $40.52 11/30/20217,470,000 shares $327.19 million +1.1%17.6%12.4 $43.80 11/15/20217,390,000 shares $281.34 million No Change17.4%13.3 $38.07 10/29/20217,390,000 shares $247.12 million +1.9%17.1%16.5 $33.44 10/15/20217,250,000 shares $249.33 million +2.1%16.8%16.1 $34.39 9/30/20217,100,000 shares $247.58 million -4.8%16.5%14.1 $34.87 9/15/20217,460,000 shares $248.94 million -2.7%17.4%11.6 $33.37 8/31/20217,670,000 shares $223.73 million -0.8%18.0%12.1 $29.17 8/13/20217,730,000 shares $211.57 million -0.9%18.1%11.7 $27.37 7/30/20217,800,000 shares $245.00 million +8.5%18.4%11.1 $31.41 7/15/20217,190,000 shares $205.49 million +6.2%17.0%10.1 $28.58 6/30/20216,770,000 shares $185.90 million +4.3%16.0%9.8 $27.46 6/15/20216,490,000 shares $158.03 million +0.3%15.3%10.4 $24.35 5/28/20216,470,000 shares $160.59 million +5.2%15.3%12.3 $24.82 5/14/20216,150,000 shares $170.05 million +11.4%14.5%11.8 $27.65 4/30/20215,520,000 shares $184.48 million -3.0%13.1%10.3 $33.42 4/15/20215,690,000 shares $188.96 million -6.7%13.5%10.9 $33.21 3/31/20216,100,000 shares $171.17 million +3.6%14.5%11.4 $28.06 3/15/20215,890,000 shares $214.69 million No Change14.0%11.1 $36.45 2/26/20215,890,000 shares $201.73 million -0.2%14.9%11.5 $34.25 2/12/20215,900,000 shares $218.30 million -1.5%16.3%11.9 $37.00Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide 1/29/20215,990,000 shares $212.11 million -5.2%16.5%12.6 $35.41 1/15/20216,320,000 shares $245.41 million +7.5%15.1%12.1 $38.83 12/31/20205,880,000 shares $159.64 million -6.8%13.9%11.7 $27.15 12/15/20206,310,000 shares $202.61 million -2.2%14.9%13 $32.11 11/30/20206,450,000 shares $165.83 million -2.9%15.2%12.4 $25.71 11/15/20206,640,000 shares $150.06 million -2.5%15.7%12.6 $22.60 10/30/20206,810,000 shares $159.49 million -2.9%16.1%12.1 $23.42 10/15/20207,010,000 shares $137.19 million +8.4%17.3%13.8 $19.57 9/30/20206,470,000 shares $110.90 million +19.8%16.5%12.3 $17.14 9/15/20205,400,000 shares $114.53 million +3.5%13.7%8.9 $21.21 8/31/20205,220,000 shares $124.24 million +3.6%13.3%8.3 $23.80 8/14/20205,040,000 shares $119.85 million +13.0%14.1%6.5 $23.78 7/31/20204,460,000 shares $87.77 million +7.7%13.2%5.6 $19.68 7/15/20204,140,000 shares $96.83 million +23.2%13.9%5 $23.39 6/30/20203,360,000 shares $79.40 million +101.2%8.9%3.7 $23.63 6/15/20201,670,000 shares $46.46 million +9.2%4.4%2 $27.82 5/29/20201,530,000 shares $47.97 million +260.0%4.6%2.1 $31.35 5/15/2020425,000 shares $14.89 million +28.2%1.6%0.7 $35.03 4/30/2020331,600 shares $8.76 million -50.7%1.2%0.6 $26.41 4/15/2020672,900 shares $10.48 million -7.8%2.5%1.4 $15.58 3/31/2020730,000 shares $21.17 million -23.0%2.7%2.3 $29.00 3/13/2020948,200 shares $15.10 million -37.6%2.9%3.8 $15.93 2/28/20201,520,000 shares $15.96 million +22.6%5.6%6.1 $10.50 2/14/20201,240,000 shares $21.74 million -3.9%4.6%6.3 $17.53 1/31/20201,290,000 shares $19.69 million -9.8%4.5%10.3 $15.26 1/15/20201,430,000 shares $16.42 million No Change5.0%12.9 $11.48 12/31/20191,430,000 shares $13.41 million -1.4%5.0%8.9 $9.38 RCUS Short Interest - Frequently Asked Questions What is Arcus Biosciences' current short interest? Short interest is the volume of Arcus Biosciences shares that have been sold short but have not yet been closed out or covered. As of October 31st, investors have sold 6,650,000 shares of RCUS short. 13.82% of Arcus Biosciences' shares are currently sold short. Learn More on Arcus Biosciences' current short interest. What is a good short interest ratio for Arcus Biosciences? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. RCUS shares currently have a short interest ratio of 9.0. Learn More on Arcus Biosciences's short interest ratio. What is a good short interest percentage for Arcus Biosciences? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 13.82% of Arcus Biosciences' floating shares are currently sold short. Is Arcus Biosciences' short interest increasing or decreasing? Arcus Biosciences saw a increase in short interest in October. As of October 31st, there was short interest totaling 6,650,000 shares, an increase of 4.9% from the previous total of 6,340,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Arcus Biosciences' float size? Arcus Biosciences currently has issued a total of 91,510,000 shares. Some of Arcus Biosciences' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Arcus Biosciences currently has a public float of 48,110,000 shares. How does Arcus Biosciences' short interest compare to its competitors? 13.82% of Arcus Biosciences' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Arcus Biosciences: Crinetics Pharmaceuticals, Inc. (7.48%), Avidity Biosciences, Inc. (12.29%), Krystal Biotech, Inc. (12.00%), ADMA Biologics, Inc. (6.43%), TG Therapeutics, Inc. (23.06%), Biohaven Ltd. (9.05%), Arcellx, Inc. (9.74%), BridgeBio Pharma, Inc. (11.71%), Ultragenyx Pharmaceutical Inc. (3.44%), Immunovant, Inc. (21.05%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Arcus Biosciences stock? Short selling RCUS is an investing strategy that aims to generate trading profit from Arcus Biosciences as its price is falling. RCUS shares are trading up $0.11 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Arcus Biosciences? A short squeeze for Arcus Biosciences occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of RCUS, which in turn drives the price of the stock up even further. How often is Arcus Biosciences' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RCUS, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies CRNX Short Interest RNA Short Interest KRYS Short Interest ADMA Short Interest TGTX Short Interest ACLX Short Interest BHVN Short Interest BBIO Short Interest RARE Short Interest IMVT Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NYSE:RCUS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
